- Home
- TPVG vs ACIU Comparison
TPVG vs ACIU Comparison
Compare TPVG & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPVG
- ACIU
- Stock Information
- Founded
- TPVG 2013
- ACIU 2003
- Country
- TPVG United States
- ACIU Switzerland
- Employees
- TPVG N/A
- ACIU N/A
- Industry
- TPVG Other Consumer Services
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- TPVG Consumer Discretionary
- ACIU Health Care
- Exchange
- TPVG Nasdaq
- ACIU Nasdaq
- Market Cap
- TPVG 286.6M
- ACIU 247.4M
- IPO Year
- TPVG N/A
- ACIU 2016
- Fundamental
- Price
- TPVG $7.01
- ACIU $1.87
- Analyst Decision
- TPVG Hold
- ACIU Strong Buy
- Analyst Count
- TPVG 5
- ACIU 2
- Target Price
- TPVG $7.31
- ACIU $12.00
- AVG Volume (30 Days)
- TPVG 357.6K
- ACIU 192.4K
- Earning Date
- TPVG 03-05-2025
- ACIU 03-13-2025
- Dividend Yield
- TPVG 17.19%
- ACIU N/A
- EPS Growth
- TPVG N/A
- ACIU N/A
- EPS
- TPVG 0.82
- ACIU N/A
- Revenue
- TPVG $108,208,000.00
- ACIU $30,136,397.00
- Revenue This Year
- TPVG N/A
- ACIU $120.91
- Revenue Next Year
- TPVG $0.42
- ACIU $13.82
- P/E Ratio
- TPVG $8.52
- ACIU N/A
- Revenue Growth
- TPVG N/A
- ACIU 84.51
- 52 Week Low
- TPVG $6.44
- ACIU $1.87
- 52 Week High
- TPVG $9.73
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- TPVG 33.35
- ACIU 23.14
- Support Level
- TPVG $7.08
- ACIU $1.95
- Resistance Level
- TPVG $7.20
- ACIU $2.05
- Average True Range (ATR)
- TPVG 0.13
- ACIU 0.12
- MACD
- TPVG -0.01
- ACIU -0.02
- Stochastic Oscillator
- TPVG 17.46
- ACIU 0.00
About TPVG TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.